Step:
THE ULTIMATE GOAL
• The most important, ultimate step of any of clinical research is to do draw inferences; that is to generalize from findings in the study to the nature of the universe around it -i.e. to answer the underlying research question • More important: Inferences have to be valid.
Truth in The Universe

Findings in the Study
Inferences
INFERENCES & VALIDITIES
• Two major levels of inferences are involved in interpreting a study The first level concerns Internal validity; the degree to which the investigator draws the correct conclusions about what actually happened in the study. For example, what to do with missing data. The second level concerns External Validity; the degree to which these conclusions could be appropriately applied to people and events outside the study: inferences.
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External Validity Internal Validity
With the goal of maximizing the validity of the inferences, the investigator reverses the process: (i) designs a study plan in which the choice of the research question, the subjects, and the measurements enhances the External Validity, and (ii) is conducive to implementation with a high degree on Internal Validity. That is to focus on the External Validity first (the design) then Internal Validity (the implementation/analysis) later.
The first step is the Sample Size Determination.
BASIC ISSUE IN INFERENCES
• One often assume there is an identifiable, existent parent population of subjects. We act as if the sample is obtained from the parent population according to a carefully defined technical procedure called random sampling.
• This is not true in real-life biomedical studies. The laboratory investigator uses animals in his projects but animals are not randomly selected from any large population of animals. The clinician, who is attempting to describe the results he has obtained with a particular therapy, but his patients is a random sample from a population of patients.
COMPARISON OF TWO MEANS
• The Problem: The endpoint is on a continuous scale; for example, a researcher is studying a drug which is to be used to reduce the cholesterol level in adult males aged 30 and over. Subjects are to be randomized into two groups, one receiving the new drug (group 1), and one a look-alike placebo (group 2). The response variable considered is the change in cholesterol level before and after the intervention. The null hypothesis to be tested is H 0 :  2 - 1 = 0 The target statistic is  = x 2 -x 1
RESULTS FOR TWO MEANS
• The null hypothesis to be tested is H 0 :  1 =  2 • The target statistic is  = x 2 -x 1 • Basic parameters are:  0 = 0,  A = d, and
• Then d 2 = (z 1- + z 1- ) 2  2 leads to total sample size:
• This required total sample size is affected by four factors: (1) The size  of the test; conventionally,  =.05 is used.
(2) The desired power (1-). This value is selected by the investigator; a power of 80% or 90% is often used.
. (4) The variance of the population. This variance  2 is the only quantity which is difficult to determine. The exact value is unknown; we may use information from similar studies or past studies or use some "upper bound".
• Specifications: Suppose a researcher is studying a drug which is used to reduce the cholesterol level in adult males aged 30 or over, and wants to test it against a placebo in a balanced randomized study. Suppose also that it is important that a reduction difference of 5 be detected (d=5). We decide to preset  =.05 and want to design a study such that its power to detect a difference between means of 5 is 95% (or  =.05). Also, the variance of cholesterol reduction (with placebo) is known to be about  2 = 36. 
COMPARISON OF 2 PROPORTIONS
• The Problem: The endpoint may be on a binary scale. For example, a new vaccine will be tested in which subjects are to be randomized into two groups of equal size: a control (not immunized) group (group 1), and an experimental (immunized) group (group 2). Subjects, in both control and experimental groups, will be challenged by a certain type of bacteria and we wish to compare the infection rates. The null hypothesis to be tested is H 0 :  2 - 1 = 0 The target statistic is  = p 2 -p 1
RESULTS FOR 2 PROPORTIONS
• The null hypothesis to be tested is H 0 : 
• This required total sample size is affected by four factors: • (1) The size  of the test; conventionally,  =.05 is used.
• (2) The desired power (1-). This value is selected by the investigator; a power of 80% or 90% is often used. obvious that the planning sample size is more difficult and a good solution requires knowledge of the scientific problem, some good idea of the magnitude of the proportions themselves.
• Specifications: Suppose we wish to conduct a clinical trial of a new therapy where the rate of successes in the control group was known to be about 5%. Further, we consider the new therapy to be superior-cost, risks, and other factors considered-if its rate of successes is about 15%. In addition, We decide to preset  =.05 and want to design a study such that its power to detect the desired difference of 15% vs. 5% is 90% (or  =.10). 
ONE-SAMPLE "TEST"
• After acquiring needed components, we state the (one-sided) hypotheses to be tested as:
• In addition, we should specify the size () and the power (1-) from to determine the sample size n:
If statistical power is specified, we can determine sample size:
Note that It is relatively simple to specify the size  and  0 , but more difficult to specify  A ; For example, one can take as  0 the response rate of the "standard treatment". Then, with a "practical estimate" of n, we can see "what it can do".
FLEMING'S RESULT
Instead of independent specification of power (1-) and Alternative Response Rate  A ; Fleming (Biometrics, 1982) prove that, for a given n the usual single-stage procedure where one rejects  0 if y( 0 ) > z 1- has power (1-) against the alternative rate: 
CASE-CONTROL STUDIES
• Both cohort and case-control-are "comparative"; the validity of the conclusions is based on a comparison.
• In a cohort study, say a clinical trial, we compare the results from the "treatment group" versus the results from the "placebo group".
• In a case-control study, we compare the "cases" versus the "controls" with respect to an exposure under investigation ("exposure" could be binary or continuous).
DIFFERENT FORMULATION
• In a cohort study, for example a two-arm clinical trial, the decision at the end is based on a "difference"; difference of two means or of two proportions. The "size" of the difference is the major criterion for sample size determination.
• In a case-control study, we compare the exposure histories of the two groups. At the end, we do not search for a difference; instead, the alternative hypothesis of a case-control study is postulated in the form of a relative risk. But the two are related.
• The data analysis maybe similar to that of a Clinical Trial where we want to compare two proportions.
• However in the design stage, the alternative hypothesis is formulated in the form of a relative risk . Since we cannot estimate or investigate "relative risk" using a casecontrol design, we would treat the given number  as an "odds ratio", the ratio of the odds of being exposed by a case divided by the odds of being exposed by a control. 
